Compare GKOS & PRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GKOS | PRI |
|---|---|---|
| Founded | 1998 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Life Insurance |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 8.9B |
| IPO Year | 2015 | 2009 |
| Metric | GKOS | PRI |
|---|---|---|
| Price | $177.33 | $296.21 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 4 |
| Target Price | $126.92 | ★ $294.00 |
| AVG Volume (30 Days) | ★ 580.7K | 167.4K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.72% |
| EPS Growth | N/A | ★ 67.10 |
| EPS | N/A | ★ 12.42 |
| Revenue | $507,442,000.00 | ★ $3,291,713,000.00 |
| Revenue This Year | $23.32 | $3.98 |
| Revenue Next Year | $27.43 | $5.08 |
| P/E Ratio | ★ N/A | $24.02 |
| Revenue Growth | ★ 32.33 | 6.56 |
| 52 Week Low | $73.16 | $230.09 |
| 52 Week High | $191.62 | $327.28 |
| Indicator | GKOS | PRI |
|---|---|---|
| Relative Strength Index (RSI) | 55.85 | 46.47 |
| Support Level | $175.04 | $254.14 |
| Resistance Level | $184.00 | $317.69 |
| Average True Range (ATR) | 5.63 | 5.71 |
| MACD | -1.97 | -1.13 |
| Stochastic Oscillator | 30.42 | 38.07 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Primerica Inc is a provider of financial services to middle-income households in the United States and Canada. The company offers life insurance, mutual funds, annuities, and other financial products, distributed on behalf of third parties. Primerica has three main subsidiaries: Primerica Financial Services, a marketing company; Primerica Life Insurance Company, a principal life insurance underwriting entity; and PFS Investments, which offers investment and savings products, brokerage services, and registered investment advisory. It has three segments Term Life Insurance; Investment and Savings Products; and Corporate and Other Distributed Products. Geogriphically, it derives a majority of its revenue from the United States.